BioTelemetry Inc (BEAT) Receives Average Recommendation of “Buy” from Analysts

BioTelemetry Inc (NASDAQ:BEAT) has received an average rating of “Buy” from the nine research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $61.50.

A number of equities analysts have recently commented on the company. Lake Street Capital lifted their price objective on BioTelemetry from $50.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 26th. Raymond James lifted their price objective on BioTelemetry from $57.00 to $66.00 and gave the stock an “outperform” rating in a research note on Friday, September 14th. BidaskClub lowered BioTelemetry from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. Finally, SunTrust Banks lifted their price objective on BioTelemetry to $67.00 and gave the stock a “buy” rating in a research note on Friday, August 31st.

In other news, insider Fred Broadway sold 90,113 shares of BioTelemetry stock in a transaction dated Friday, September 28th. The stock was sold at an average price of $65.00, for a total value of $5,857,345.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Daniel Wisniewski sold 31,000 shares of the business’s stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $60.45, for a total value of $1,873,950.00. Following the transaction, the senior vice president now owns 57,291 shares in the company, valued at $3,463,240.95. The disclosure for this sale can be found here. Insiders sold 122,363 shares of company stock worth $7,810,901 over the last quarter. 9.60% of the stock is currently owned by corporate insiders.



A number of institutional investors and hedge funds have recently modified their holdings of BEAT. Thompson Davis & CO. Inc. increased its stake in BioTelemetry by 112.0% during the second quarter. Thompson Davis & CO. Inc. now owns 2,650 shares of the medical research company’s stock valued at $119,000 after acquiring an additional 1,400 shares during the period. Mount Yale Investment Advisors LLC bought a new position in BioTelemetry during the first quarter valued at about $125,000. IFP Advisors Inc increased its stake in BioTelemetry by 163.0% during the third quarter. IFP Advisors Inc now owns 2,927 shares of the medical research company’s stock valued at $189,000 after acquiring an additional 1,814 shares during the period. OppenheimerFunds Inc. bought a new position in BioTelemetry during the second quarter valued at about $205,000. Finally, Xact Kapitalforvaltning AB bought a new position in BioTelemetry during the first quarter valued at about $211,000. Hedge funds and other institutional investors own 93.76% of the company’s stock.

Shares of NASDAQ:BEAT traded down $0.80 on Monday, reaching $49.76. The company had a trading volume of 378,714 shares, compared to its average volume of 465,435. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.29 and a quick ratio of 2.12. The stock has a market capitalization of $1.66 billion, a P/E ratio of 51.30, a P/E/G ratio of 3.34 and a beta of 1.41. BioTelemetry has a twelve month low of $23.30 and a twelve month high of $66.02.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Wednesday, July 25th. The medical research company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.15. The business had revenue of $101.36 million for the quarter, compared to analyst estimates of $95.87 million. BioTelemetry had a positive return on equity of 18.02% and a negative net margin of 0.39%. The firm’s revenue for the quarter was up 74.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.23 earnings per share. As a group, research analysts expect that BioTelemetry will post 1.51 EPS for the current fiscal year.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Read More: Understanding Market Liquidity

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply